AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

AstraZeneca PLC (LSE:AZN) 今日宣布，公司非执行董事长Michel Demaré以每股117.927465英镑的价格购买了2,000股普通股。此次交易在伦敦证券交易所进行。 根据欧盟《市场滥用条例》的要求，Demaré的这次购买行为已被报告。这是一次简单的股票收购，没有其他需要报告的汇总交易。这种购买行为是上市公司管理层人员正常投资活动的一部分。

Arab Finance: AstraZeneca Egypt is planning to inject $50 million into new investments in Egypt, equivalent to nearly 50% of the company’s capital, the firm’s Country President Hatem Werdany stated.

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

特拉华州威尔明顿 - AstraZeneca和第一三共的datopotamab deruxtecan (Dato-DXd)在一项针对特定肺癌患者的III期试验中显示出相比化疗改善总生存期(OS)的趋势。这项名为TROPION-Lung01的研究涉及先前至少接受过一线治疗的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成年患者。 在整体试验人群中，OS结果在数值上favored Dato-DXd优 ...